Use of artificial pancreas devices added nearly 2.5 hours of time in near normoglycemia over 24 hours in patients with type 1 diabetes, a meta-analysis of randomized clinical trials showed.
The improvement versus control subjects was primarily because of the favorable effect of the closed loop glucose control systems in the overnight period, authors of the meta-analysis reported in the BMJ.
Both single and dual hormone systems had robust results in the meta-anaysis, said lead researcher Eleni Bekiari, MD, PhD, of Aristotle University of Thessaloniki, Greece, and her coinvestigators.
Results were likewise robust for an analysis restricted to trials conducted under normal living conditions and no remote monitoring, supporting the convenience and ease of use of these systems, according to Dr. Bekiari and her colleagues.
“Overall, our results reflect the progress made over recent decades of extensive research and development in artificial pancreas use,” they wrote.
Despite the findings, more research needs to be done, they added, since the individual clinical trials supporting use of closed-loop systems in type 1 diabetes have included relatively few patients and have had short follow-up durations.
The systematic review and meta-analysis by Dr. Bekiari and her colleagues was based on 40 randomized controlled trials involving a total of 1,027 participants. The primary outcome of the analysis was proportion of time that sensor glucose level was in the normoglycemic range of 3.9-10 mmol/L.
Overall, use of the systems was associated with 140 additional minutes in near normoglycemia over 24 hours, with a 9.62% mean weighted difference (95% confidence interval, 7.54%-11.7%), reported data show.
The favorable effect was even more evident on overnight measures, the investigators said, with a weighted mean difference of 15.15% (95% CI, 12.21%-18.09%).
Results were similar even when the analysis was limited to studies that had a low risk of bias, and also when the analysis was limited to studies of unsupervised patients in normal living conditions, according to Dr. Bekiari and her associates.
Artificial pancreas use also had favorable impacts on time in hyperglycemia over the entire day. Compared with controls, time with glucose concentrations less than 10 mmol/L were shortened by about 2 hours, the investigators said.
Likewise, mean levels of sensor blood glucose over 24 hours fell by 0.48 mmol/L compared with control treatment (95% CI, 0.3-0.66 mmol/L), they reported.
Taken together, these findings suggest artificial pancreas systems are efficacious and safe for patients with type 1 diabetes, the investigators concluded.
“Further research with rigorous studies, cooperation of research groups in terms of outcome reporting, and cost-effectiveness data are required to verify these findings and support adoption of artificial pancreas systems in clinical practice,” they wrote.
Dr. Bekiari reported no disclosures. Her coauthors reported disclosures related to Medtronic, Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim and others outside of the submitted work.
SOURCE: Bekiai E et al. BMJ 2018;361:k1310.